4.0
Aug 23, 2008
Current employee
Recommend
CEO approval
Business outlook
Pros
-Oncology product line -Great science -Hot company, great brand name -Generally good people can be found across the company in various divisions
Cons
Corporatization and growth. Trend of commercial dictating development too much. Potential buyout by Roche. The other thing to be aware of is the changing nature of the biopharma field in conjunction with the changing landscape of health system in the US. Biotech drugs are garnering increasing scrutiny due to price and companies like Genentech will be pushed to demonstrate value above and beyond what it has done so far. With regards to this the free ride is over.